Healthy Clinical Trial
Official title:
Gastrointestinal Responses to Millet and Oats Breakfast Interventions Assessed by MRI
Breakfast porridges made from milled grains are commonly eaten worldwide. Traditionally
different grains are used in different countries. For example, oats are more common in the
Anglo-Saxon countries whilst millet is very common in parts of India and Africa. However the
nutritional value of different grains and their potential effects on the body may vary
dramatically: for example the effect on blood sugar, on how fast the stomach empties after
eating and how full people may feel.
RESEARCH QUESTION: The investigators think that a pearl millet breakfast will cause a smaller
rise in blood sugar compared with an oat breakfast containing the same number of calories.
The investigators also think that there will be a difference in how full people feel and how
fast their stomach will empty. These 2 breakfasts will be fed to each one of 26 healthy
volunteers, one week apart. A safe medical imaging method (MRI) will be used to look at how
quickly the breakfast empty from the stomach and how this affects the small bowel. Blood
glucose levels will be measured using a finger prick test (the same as used by diabetics) and
some small blood samples will be taken from a vein in the arm to measure the chemicals
released by the gut after feeding gut hormones.
Background: Porridge breakfasts from various grains are a staple source of energy for many
populations worldwide. The grains used in the porridges differ between regions, mostly due to
the crops historically grown. For example, oats are more common in the Anglo-Saxon countries
whilst millet is very common in parts of India and Africa. Consumption of whole grains has
been associated with a variety of health benefits ranging from lower blood glucose levels,
improved insulin responses, reduced cholesterol and increased diversity of the microbiota. Of
particular interest to this study are recent suggestions that different grains, and
particularly millet grains, may have enhanced health benefits on glucose and insulin
metabolism. This may be due to different rates of digestion and absorption, for example,
because of grain specific differences in starch digestibility. This could affect gastric
emptying and, in turn, post prandial glycaemia and impact on satiety. However little is known
about possible differences in gastric emptying between breakfast porridges from different
grains and possible relationship with glucose, insulin and appetite.
The research group in Nottingham has world-leading expertise in imaging foods in the body and
gastrointestinal function using non-invasive Magnetic Resonance Imaging (MRI) techniques
which are particularly well suited for this kind of investigations study.
Aims:
1. to collect data on postprandial glucose levels and hormone peptide response of
isoenergetic breakfast porridges made from oats and pearl millet.
2. to collect data on their gastric emptying and satiety.
3. to compare postprandial glucose levels, gastric emptying and satiety for the treatments
4. to explore relationships between glucose levels, gastric emptying and satiety.
Experimental protocol and methods: 26 healthy volunteers will participate in this 2-way
study. They will attend one morning for each study, with the studies separated by
approximately a week. Before the test meal, and after that approximately every 15 min for 2
hours the level of sugar (glucose) in their blood will be measured using the finger prick
method, as diabetics commonly do to monitor their blood sugars. Venous blood samples will
also be collected from a cannula placed in the forearm to measure gut hormones such as
Peptide YY, GIP, GLP-1 and insulin. The subjects will be scanned on a research dedicated 1.5T
MRI scanner. The subjects will be scanned at baseline, immediately after the test meal and
then every 30 minutes for 2 hours postprandially. At baseline and every time the subjects
come out of the MRI scanner they will be asaked to rate their feelings of fullness, hunger
and appetite on 100mm VAS scales. Each subject will be fed two isoenergetic breakfast meals
-one on each visit: Oat and Pearl millet breakfast porridge sourced from supermarkets or food
manufacturers. These will be cooked in water to avoid confounding factor with milk. The test
breakfast will have 220 kcal (slightly higher than a commonly recommended average portion of
~185 kcal). After this the subjects will be asked to eat as much of a pasta meal as they wish
and note how much they have eaten as an objective measure of food consumption. The subjects
will also complete a food diary for the rest of the day.
Measurable endpoints/ statistical power Primary endpoint: Incremental Area Under the Curve of
post prandial blood glucose up to 2h (AUC2h) Secondary endpoints: Area Under the Curve of
post prandial gastric volumes up to 2h (AUC2h), postprandial hormone peptide response,
insulin and post prandial VAS scores up to 2h.
Descriptive and exploratory measurements: Time to Peak of blood glucose; Area Under the Curve
for appetite (Fullness, Hunger, Prospective food consumption) up to 2h. The amount of pasta
meal eaten ad libitum. Energy intake for the day from food diaries.
Correlations between blood, MRI and satiety data. Using Satiety data (Hunger) from our pilot
study, we can calculate sample size needed using a crossover, paired design with alpha=0.05
and a power of 80% using n=26 participants.
The data will be assessed for normality using the Shapiro-Wilk test and other such methods as
appropriate. Where normally distributed, endpoints will be assessed using parametric methods.
T test (primary endpoint) and AUC2h (secondary endpoints). T test of Time to Peak.
Correlation (Pearson's or Spearman) between blood glucose, MRI and satiety data.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |